Alternative BCG strains may help address ongoing supply challenges in NMIBC

Ongoing supply shortages of the FDA-approved TICE BCG strain complicate treatment for high-risk non-muscle invasive bladder cancer (NMIBC) in the US, prompting clinical trials like SWOG S1602 which found the Tokyo strain of BCG potentially as effective and available alternative. This may influence broader adoption of non-TICE BCG strains and recombinant BCG variants to address supply and toxicity issues in NMIBC care.

This Wire brief sits within Fusion42's coverage of Health.